Eliquis (Apixaban) meets endpoints in ARISTOTLE - Stock Price Reaction premature
BMY announced positive topline data from the ARISTOTLE trial, Eliquis met both, the primary (reduction in stroke and embolism) and secondary endpoint (reduction in major bleeding and combined rate of ischemic stroke/embolism/all cause death). Post announcement of the data, BMY stock price has jumped 6%, while BAY stock price is down 5%. The stock price reaction is a bit premature, as detailed data is crucial to understand Eliquis relative efficacy/safety compared to Pradaxa and Xarelto. From a trial design perspective, the clinical data on Xarelto and Eliquis are not directly comparable based on CHADS2 score, ARISTOTLE has primarily enrolled the low to medium risk population, while ROCKET AF has primarily enrolled moderate to high-risk population. A subgroup analysis would define the positioning of each drug in the market. It would be important to …
COMPANIES MENTIONED
PFE, BMY, BAYN, JNJ,
PFE, BMY, BAYN, JNJ,
